Somatic Mutation Testing
Testing for the presence of cancer requires the utmost personal care and consideration. Somatic mutation testing is enormously beneficial for improving the prognosis and the quality of life of cancer-affected patients. Our team of hereditary and somatic cancer experts will support you during every step of the process.
Identifying Somatic Mutations for Tumor Profiling
Every cancer cell can evolve its own pattern of mutated genes.
Each person's cancer, and even parts of a single tumor, can become completely unique. This has implications with respect to diagnosis, prognosis and treatment response. The presence of recurrent somatic mutations allows us to create a detailed molecular fingerprint of the tumor and to identify important tumor subtypes.
How Can Somatic Genetic Testing Help Patient Care?
Somatic mutation analysis is a standard of practice for tumors in order to identify therapeutic sensitizing and resistance mutations. This allows a finer assessment of the diagnosis and prognosis and targeted therapies directed towards the individual patients tumor profile.
What Do We Know About Somatic Mutations?
Cancer is one of the leading causes of morbidity and mortality worldwide. Cancer can be the result of a genetic predisposition that is inherited from family members (germline (hereditary) gene mutation) or it can be the result of the acquired mutations accumulated during a lifetime (somatic (acquired) mutation).
Unlike regular cells, cancer cells do not experience physiological elimination of “programmed cell death” or “apoptosis”; instead they continue to grow and divide. Tumor cells show uncontrolled proliferation if there are mutations in the genes involved in cell division .
Somatic Mutation Testing for Myeloid Tumors
Genetic testing of myeloid tumors can help you make accurate diagnoses, provide prognoses, choose appropriate therapy and counsel patients
Note
Hotspot targeted mutation testing is unavailable in the US for the following mutations: BRAF c.1799T>A p.V600E, EGFR c.2573T>G, p.L858R, KRAS c.35G>A, p.G12D, KRAS c.38G>A, p.G13D, KRAS c.35G>T p.G12V, NRAS c.181C>A p.Q61K, NRAS c.34G>T, p.G12C, NRAS c.35G>A, p.G12D, NRAS c.182A>G, p.Q61R.
Resources
Useful Links
Downloads
Solid Tumor Panel – Product Sheet
Providing knowledge to battle cancer
Myeloid Tumor Panel – Product Sheet
The targeted approach to detecting myeloid malignancies
Scientific Publications
Two Distinct Disorders Resulting From Mutations in One Gene
Mutations in a given gene are usually associated with a single genetic disorder. Combined analysis of published case reports and data from CENTOGENE’s uniquely large database revealed that the NTRK2 […]
Related Webinars
CentoLCV – El nuevo estándar para detectar desequilibrios cromosómicos
Mira el webinar sobre CentoLCV™, nuestro nuevo análisis integral de variación de número de copias (CNV), y aprender por qué es el nuevo estándar para establecer diagnósticos moleculares más precisos […]
CentoLCV – The New Standard for Detecting Chromosomal Imbalances
Watch Dr. Peter Bauer, MD, Chief Genomic Officer at CENTOGENE, as he discusses CentoLCV, our comprehensive Large Copy number Variation (CNV) analysis, and why it is the new standard for establishing […]
Genetics in Parkinson’s Disease – Lessons from a Global Cohort
Join our next webinar discussing Parkinson’s Disease, one of the most common neurodegenerative disorders manifested by a broad spectrum of motor and non-motor features. Prof. Peter Bauer, MD, […]
Get in Touch With Our Customer Support
Our consultation service is available in several languages.
+49 (0) 381 80 113 - 416
Mon. – Fri. 8 a.m. – 6:30 p.m. CET
For Spanish and Portuguese Partners: